Istavel 25 Mg (Sitagliptin) – Product Overview

Istavel 25 Mg is a prescription oral antidiabetic medication manufactured by Sun Pharmaceutical Industries Ltd. The product is formulated for the management of type 2 diabetes mellitus and is supplied in a strip containing ten tablets. Available pack sizes include 100, 200, and 300 tablets, each tablet delivering 25 mg of sitagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor. Shipping generally takes between six and fifteen days, depending on the destination and customs processing.

What is Istavel 25 Mg (Sitagliptin)

Sitagliptin, the active ingredient in Istavel, belongs to the class of DPP‑4 inhibitors that enhance the body’s incretin hormones. By blocking the DPP‑4 enzyme, sitagliptin slows the degradation of glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP), leading to increased insulin secretion when blood glucose rises and decreased glucagon release. This mechanism helps lower fasting and post‑prandial glucose levels without causing excessive hypoglycemia in most patients. The United States Food and Drug Administration (FDA) first approved sitagliptin in 2006, and it remains a cornerstone therapy for type 2 diabetes. For detailed prescribing information see the FDA label. Insights from the National Institutes of Health further support its role in glycemic control.

Uses and Benefits

Istavel 25 Mg is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Clinical studies have demonstrated that sitagliptin monotherapy, as well as combination therapy with metformin or sulfonylureas, provides a modest but clinically meaningful reduction in HbA1c, typically ranging from 0.5% to 0.8% over 24 weeks. In addition, cardiovascular outcome trials have shown a neutral effect on major adverse cardiovascular events, making it a safe option for patients with existing heart disease. The medication is also associated with weight neutrality, which is advantageous for patients who are overweight or obese.

How It Works

The pharmacodynamic action of sitagliptin centers on the inhibition of the DPP‑4 enzyme, which is expressed on pancreatic beta cells, endothelial cells, and immune cells. When DPP‑4 is blocked, circulating levels of GLP‑1 and GIP are prolonged, enhancing glucose‑dependent insulin secretion and suppressing glucagon release after meals. This glucose‑dependent mechanism reduces the likelihood of hypoglycemia, as insulin release is directly tied to rising glucose concentrations. Additionally, sitagliptin has been shown to modestly improve beta‑cell function over time, potentially contributing to longer‑term glycemic stability. Evidence from Drugs.com corroborates these findings.

Dosage Guidelines

Istavel 25 Mg is typically prescribed as one tablet taken once daily, with or without food, at the same time each day. For patients with moderate to severe renal impairment (estimated glomerular filtration rate <30 mL/min/1.73 m²), the recommended dose is reduced to 25 mg every other day to avoid accumulation. The dosing regimen should be individualized based on the patient's overall health status, concomitant antidiabetic therapy, and physician judgment. It is essential that patients do not adjust their dose without consulting a healthcare professional, and that liver function is monitored periodically during treatment.

Side Effects

Like all medications, Istavel 25 Mg may cause adverse effects. The most commonly reported side effects include nasopharyngitis, urinary tract infections, and mild hypoglycemia when used in combination with insulin or sulfonylureas. Less frequent but clinically important adverse events comprise acute pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angioedema. Patients should be advised to seek immediate medical attention if they experience persistent abdominal pain, severe joint discomfort, or signs of an allergic reaction such as swelling of the face, lips, or tongue.

Warnings and Precautions

Prior to initiating therapy with Istavel, clinicians should assess renal function, history of pancreatitis, and any prior hypersensitivity to sitagliptin or any component of the formulation. Istavel is classified as Pregnancy Category B; however, pregnant or breastfeeding women should only use the medication if the potential benefits outweigh the risks, as determined by a qualified healthcare provider. Patients with a history of heart failure or chronic kidney disease should be monitored closely, and dose adjustments may be required. Concomitant use of strong CYP3A4 inducers or inhibitors may affect sitagliptin exposure and should be reviewed.

Frequently Asked Questions

What is the primary indication for Istavel 25 Mg?

Istavel 25 Mg is indicated for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.

How should Istavel be stored?

Store the medication at room temperature, away from moisture and heat, and keep the strip sealed until ready for use.

Can Istavel be taken with other diabetes medications?

Yes, Istavel can be combined with metformin, sulfonylureas, or insulin, but dose adjustments may be necessary to minimize the risk of hypoglycemia.

Is weight gain a concern with Istavel therapy?

Clinical data suggest that sitagliptin is weight‑neutral; patients typically do not experience significant weight gain or loss when using Istavel.

What should I do if I miss a dose?

If a dose is missed, take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, skip the missed dose and resume the regular schedule.

Related Products

• Famotidine 20mg (Generic)
• Omesec 20 mg (Omeprazole)
• Pantocid DSR (Pantoprazole/Domperidone)
• Famotidine 40mg (Generic)
• Famocid 20mg (Famotidine)
• Famocid 40mg (Famotidine)
• Famocid (Famotidine)
• Supatret 0.04% Gel (Tretinoin)
• Supatret 0.1% Gel (Tretinoin)
• Supatret C Gel (Clindamycin/Tretinoin)
• Supatret Gel (Tretinoin)
• Acitretin 25mg (Generic)